Vincent A. Miller
Foundation Medicine
Publications 778
#1Ilya G. Serebriiskii (Kazan: Kazan Federal University)H-Index: 27
#2Caitlin F. Connelly (Foundation Medicine)H-Index: 4
Last.Sanjeevani Arora (Fox Chase Cancer Center)H-Index: 4
view all 13 authors...
Colorectal cancer (CRC) is increasingly appreciated as a heterogeneous disease, with factors such as microsatellite instability (MSI), cancer subsite within the colon versus rectum, and age of diagnosis associated with specific disease course and therapeutic response. Activating oncogenic mutations in KRAS and NRAS are common in CRC, driving tumor progression and influencing efficacy of both cytotoxic and targeted therapies. The RAS mutational spectrum differs substantially between tumors arisin...
#1Sally E. Trabucco (Foundation Medicine)H-Index: 3
#2Kyle Gowen (Foundation Medicine)H-Index: 10
Last.Garrett M. Frampton (Foundation Medicine)H-Index: 36
view all 16 authors...
Microsatellite instability (MSI) is an important biomarker for predicting response to immune checkpoint inhibitor therapy, as emphasized by the recent checkpoint inhibitor approval for MSI-H solid tumors. Here we describe and validate a novel method for determining MSI status from a next-generation sequencing comprehensive genomic profiling assay using formalin-fixed, paraffin-embedded samples. This method is 97% (65/67) concordant with current standards, PCR and immunohistochemistry. We further...
#1Apostolia Maria Tsimberidou (University of Texas MD Anderson Cancer Center)H-Index: 49
#2David K. Hong (University of Texas MD Anderson Cancer Center)H-Index: 52
Last.S-M. Tu (University of Texas MD Anderson Cancer Center)
view all 0 authors...
#1Jacqulyne Ponville Robichaux (University of Texas MD Anderson Cancer Center)H-Index: 3
#2Yasir Elamin (University of Texas MD Anderson Cancer Center)H-Index: 6
Last.Huiying Sun (University of Texas MD Anderson Cancer Center)H-Index: 3
view all 0 authors...
Summary We characterized the landscape and drug sensitivity of ERBB2 (HER2) mutations in cancers. In 11 datasets (n = 211,726), ERBB2 mutational hotspots varied across 25 tumor types. Common HER2 mutants yielded differential sensitivities to eleven EGFR/HER2 tyrosine kinase inhibitors (TKIs) in vitro, and molecular dynamics simulations revealed that mutants with a reduced drug-binding pocket volume were associated with decreased affinity for larger TKIs. Overall, poziotinib was the most potent H...
#1Jonathan Keith Killian (Foundation Medicine)H-Index: 2
#2Dean Pavlick (Foundation Medicine)H-Index: 8
Last.Nhu Ngo (Foundation Medicine)
view all 0 authors...